A detailed history of Amalgamated Bank transactions in Ardelyx, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 8,094 shares of ARDX stock, worth $42,655. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,094
Previous 8,094 -0.0%
Holding current value
$42,655
Previous $60,000 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$5.89 - $9.31 $1,507 - $2,383
256 Added 3.27%
8,094 $60,000
Q1 2024

Apr 23, 2024

SELL
$6.05 - $9.74 $121,326 - $195,325
-20,054 Reduced 71.9%
7,838 $57,000
Q4 2023

Feb 06, 2024

SELL
$3.29 - $6.64 $1,339 - $2,702
-407 Reduced 1.44%
27,892 $173,000
Q2 2023

Aug 11, 2023

BUY
$3.23 - $4.95 $91,405 - $140,080
28,299 New
28,299 $95,000
Q2 2022

Aug 15, 2022

SELL
$0.51 - $1.17 $7,530 - $17,276
-14,766 Closed
0 $0
Q1 2022

Jun 30, 2022

SELL
$0.65 - $1.18 $484 - $879
-745 Reduced 4.8%
14,766 $16,000
Q4 2021

Feb 15, 2022

BUY
$0.86 - $1.7 $718 - $1,419
835 Added 5.69%
15,511 $17,000
Q3 2021

Oct 29, 2021

SELL
$1.27 - $8.17 $406 - $2,614
-320 Reduced 2.13%
14,676 $19,000
Q2 2021

Aug 16, 2021

BUY
$6.55 - $8.98 $29,370 - $40,266
4,484 Added 42.66%
14,996 $114,000
Q1 2021

May 13, 2021

SELL
$6.1 - $7.69 $6,386 - $8,051
-1,047 Reduced 9.06%
10,512 $70,000
Q4 2020

Feb 12, 2021

BUY
$5.05 - $7.1 $949 - $1,334
188 Added 1.65%
11,559 $74,000
Q3 2020

Oct 30, 2020

SELL
$5.25 - $7.08 $1,554 - $2,095
-296 Reduced 2.54%
11,371 $60,000
Q2 2020

Aug 10, 2020

BUY
$5.37 - $8.11 $62,651 - $94,619
11,667 New
11,667 $81,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $815M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.